Logo image of CMPS

COMPASS PATHWAYS PLC (CMPS) Stock Fundamental Analysis

NASDAQ:CMPS - Nasdaq - US20451W1018 - ADR - Currency: USD

4.31  -0.05 (-1.15%)

After market: 4.288 -0.02 (-0.51%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CMPS. CMPS was compared to 551 industry peers in the Biotechnology industry. CMPS may be in some trouble as it scores bad on both profitability and health. CMPS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CMPS had negative earnings in the past year.
In the past year CMPS has reported a negative cash flow from operations.
In the past 5 years CMPS always reported negative net income.
In the past 5 years CMPS always reported negative operating cash flow.
CMPS Yearly Net Income VS EBIT VS OCF VS FCFCMPS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CMPS's Return On Assets of -47.05% is in line compared to the rest of the industry. CMPS outperforms 51.18% of its industry peers.
CMPS's Return On Equity of -84.96% is in line compared to the rest of the industry. CMPS outperforms 49.36% of its industry peers.
Industry RankSector Rank
ROA -47.05%
ROE -84.96%
ROIC N/A
ROA(3y)-53.97%
ROA(5y)-43.08%
ROE(3y)-67.74%
ROE(5y)-51.83%
ROIC(3y)N/A
ROIC(5y)N/A
CMPS Yearly ROA, ROE, ROICCMPS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CMPS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPS Yearly Profit, Operating, Gross MarginsCMPS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, CMPS has more shares outstanding
CMPS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CMPS is higher compared to a year ago.
CMPS Yearly Shares OutstandingCMPS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CMPS Yearly Total Debt VS Total AssetsCMPS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -2.07, we must say that CMPS is in the distress zone and has some risk of bankruptcy.
CMPS's Altman-Z score of -2.07 is in line compared to the rest of the industry. CMPS outperforms 52.27% of its industry peers.
CMPS has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.14, CMPS is not doing good in the industry: 67.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -2.07
ROIC/WACCN/A
WACCN/A
CMPS Yearly LT Debt VS Equity VS FCFCMPS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 8.82 indicates that CMPS has no problem at all paying its short term obligations.
CMPS's Current ratio of 8.82 is fine compared to the rest of the industry. CMPS outperforms 74.05% of its industry peers.
CMPS has a Quick Ratio of 8.82. This indicates that CMPS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CMPS (8.82) is better than 74.05% of its industry peers.
Industry RankSector Rank
Current Ratio 8.82
Quick Ratio 8.82
CMPS Yearly Current Assets VS Current LiabilitesCMPS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

CMPS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.29%, which is quite good.
EPS 1Y (TTM)14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CMPS will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.52% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.51%
EPS Next 2Y15.67%
EPS Next 3Y12.29%
EPS Next 5Y9.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMPS Yearly Revenue VS EstimatesCMPS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CMPS Yearly EPS VS EstimatesCMPS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMPS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMPS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPS Price Earnings VS Forward Price EarningsCMPS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPS Per share dataCMPS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

CMPS's earnings are expected to grow with 12.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.67%
EPS Next 3Y12.29%

More info and screens

0

5. Dividend

5.1 Amount

CMPS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPASS PATHWAYS PLC

NASDAQ:CMPS (8/7/2025, 5:22:24 PM)

After market: 4.288 -0.02 (-0.51%)

4.31

-0.05 (-1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-29 2025-10-29
Inst Owners55.64%
Inst Owner Change-0.1%
Ins Owners1.8%
Ins Owner Change1.65%
Market Cap403.25M
Analysts82.67
Price Target15.75 (265.43%)
Short Float %10.87%
Short Ratio2.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.22%
Min EPS beat(2)6.08%
Max EPS beat(2)20.36%
EPS beat(4)4
Avg EPS beat(4)8.15%
Min EPS beat(4)2.27%
Max EPS beat(4)20.36%
EPS beat(8)4
Avg EPS beat(8)-11.49%
EPS beat(12)7
Avg EPS beat(12)-3.88%
EPS beat(16)10
Avg EPS beat(16)0.19%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.19%
PT rev (3m)-5.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.23%
EPS NY rev (1m)1.43%
EPS NY rev (3m)10.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.48
P/tB 2.48
EV/EBITDA N/A
EPS(TTM)-1.98
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS0
BVpS1.74
TBVpS1.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.05%
ROE -84.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.97%
ROA(5y)-43.08%
ROE(3y)-67.74%
ROE(5y)-51.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.82
Quick Ratio 8.82
Altman-Z -2.07
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)69.7%
Cap/Depr(5y)102.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.79%
EPS Next Y28.51%
EPS Next 2Y15.67%
EPS Next 3Y12.29%
EPS Next 5Y9.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.92%
EBIT Next 3Y3.42%
EBIT Next 5Y11.54%
FCF growth 1Y-26.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.89%
OCF growth 3YN/A
OCF growth 5YN/A